KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Michael David Smith Sells 10,014 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) VP Michael David Smith sold 10,014 shares of the firm’s stock in a transaction that occurred on Wednesday, April 28th. The stock was sold at an average price of $25.76, for a total transaction of $257,960.64. Following the sale, the vice president now owns 10,014 shares of the company’s stock, valued at approximately $257,960.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of KALV stock opened at $24.96 on Tuesday. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.03 and a 52 week high of $45.00. The stock has a market capitalization of $606.73 million, a PE ratio of -12.00 and a beta of 2.13. The firm has a 50 day moving average of $27.33 and a two-hundred day moving average of $22.80.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, March 11th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.04. KalVista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 47.45%. On average, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on KALV. Zacks Investment Research upgraded shares of KalVista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a report on Monday, March 29th. SVB Leerink restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, March 16th. Jefferies Financial Group raised their price target on shares of KalVista Pharmaceuticals from $34.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 9th. Roth Capital lifted their target price on shares of KalVista Pharmaceuticals from $30.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, February 25th. Finally, Needham & Company LLC lifted their target price on shares of KalVista Pharmaceuticals from $25.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 26th. Seven investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $47.43.

A number of hedge funds have recently modified their holdings of KALV. Albion Financial Group UT purchased a new position in KalVista Pharmaceuticals in the 4th quarter valued at approximately $33,000. Lindbrook Capital LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth $46,000. Citigroup Inc. lifted its position in shares of KalVista Pharmaceuticals by 289.5% during the 4th quarter. Citigroup Inc. now owns 3,576 shares of the specialty pharmaceutical company’s stock worth $68,000 after purchasing an additional 2,658 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth $81,000. Finally, SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth $104,000. 90.19% of the stock is owned by institutional investors.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: P/E Growth (PEG)

Insider Buying and Selling by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.